Amy Turriff1, Delphine Blain2, Morgan Similuk3, Barbara Biesecker4, Henry Wiley5, Catherine Cukras5, Paul A Sieving6. 1. Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: turriffa@mail.nih.gov. 2. Ophthalmic Genetics and Visual Function Branch, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA. 3. Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. 4. Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA. 5. Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA. 6. National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract
PURPOSE: To describe the motivations, expectations, and other factors men with X-linked retinoschisis (XLRS) consider when making decisions to participate in an early phase ocular gene therapy clinical trial. DESIGN: Qualitative interview study. METHODS: Men with XLRS who were considering participation in a phase I/IIa ocular gene therapy clinical trial at the National Eye Institute were eligible for this study. Trial participants (n = 9) were interviewed prior to receiving the gene transfer and then at 3 and 12 months later. Trial participation decliners (n = 2) were interviewed at an initial visit and 12 months later. Those screened for the trial and found ineligible (n = 2) were interviewed at an initial visit only. Interviews were transcribed, coded, and analyzed thematically. RESULTS: Interview participants described decision making factors as risk-benefit assessments, personal intuition, trust in the study team, and religious faith. Altruism and the potential for therapeutic benefit were the main motives for trial participation, whereas the uncertainty of risks and benefits was the reason 2 men declined participation. Although most participants hoped for direct benefit, no one expected to benefit. Almost all interview participants considered their decision straightforward and were satisfied with their decision when interviewed over time. Meaningful relationships with the study team and perceived secondary benefits to participation contributed to positive trial experiences. CONCLUSIONS: Engaging prospective research participants in a discussion about their hopes, expectations, and personal factors provides a more complete understanding of patient decision making and may help support informed choices to participate in clinical trials for XLRS. Published by Elsevier Inc.
PURPOSE: To describe the motivations, expectations, and other factors men with X-linked retinoschisis (XLRS) consider when making decisions to participate in an early phase ocular gene therapy clinical trial. DESIGN: Qualitative interview study. METHODS:Men with XLRS who were considering participation in a phase I/IIa ocular gene therapy clinical trial at the National Eye Institute were eligible for this study. Trial participants (n = 9) were interviewed prior to receiving the gene transfer and then at 3 and 12 months later. Trial participation decliners (n = 2) were interviewed at an initial visit and 12 months later. Those screened for the trial and found ineligible (n = 2) were interviewed at an initial visit only. Interviews were transcribed, coded, and analyzed thematically. RESULTS: Interview participants described decision making factors as risk-benefit assessments, personal intuition, trust in the study team, and religious faith. Altruism and the potential for therapeutic benefit were the main motives for trial participation, whereas the uncertainty of risks and benefits was the reason 2 men declined participation. Although most participants hoped for direct benefit, no one expected to benefit. Almost all interview participants considered their decision straightforward and were satisfied with their decision when interviewed over time. Meaningful relationships with the study team and perceived secondary benefits to participation contributed to positive trial experiences. CONCLUSIONS: Engaging prospective research participants in a discussion about their hopes, expectations, and personal factors provides a more complete understanding of patient decision making and may help support informed choices to participate in clinical trials for XLRS. Published by Elsevier Inc.
Authors: Scott Y H Kim; Lauren Schrock; Renee M Wilson; Samuel A Frank; Robert G Holloway; Karl Kieburtz; Raymond G de Vries Journal: IRB Date: 2009 Sep-Oct
Authors: Daniel P Sulmasy; Alan B Astrow; M Kai He; Damon M Seils; Neal J Meropol; Ellyn Micco; Kevin P Weinfurt Journal: Cancer Date: 2010-08-01 Impact factor: 6.860
Authors: Kevin P Weinfurt; Liana D Castel; Yun Li; Daniel P Sulmasy; Andrew M Balshem; Al B Benson; Caroline B Burnett; Darrell J Gaskin; John L Marshall; Elyse F Slater; Kevin A Schulman; Neal J Meropol Journal: Cancer Date: 2003-07-01 Impact factor: 6.860
Authors: Kevin P Weinfurt; Damon M Seils; Janice P Tzeng; Kate L Compton; Daniel P Sulmasy; Alan B Astrow; Nicholas A Solarino; Kevin A Schulman; Neal J Meropol Journal: Med Decis Making Date: 2008-03-31 Impact factor: 2.583
Authors: Myra B McGuinness; Alexis Ceecee Britten-Jones; Lauren N Ayton; Robert P Finger; Fred K Chen; John Grigg; Heather G Mack Journal: Transl Vis Sci Technol Date: 2022-02-01 Impact factor: 3.283
Authors: Hae Lin Cho; Scott Y H Kim; Courtney Fitzhugh; Matthew Hsieh; John Tisdale; Christine Grady Journal: Biol Blood Marrow Transplant Date: 2020-03-19 Impact factor: 5.742
Authors: Heather G Mack; Fred K Chen; John Grigg; Robyn Jamieson; John De Roach; Fleur O'Hare; Alexis Ceecee Britten-Jones; Myra McGuinness; Nicole Tindill; Lauren Ayton Journal: BMJ Open Date: 2021-06-22 Impact factor: 2.692